Class summary at a glance.

Every drug in the Janus Kinase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $2.49Bcombined across class
Total Rx claims: 347K67K unique beneficiaries
Generic mfrs (active): 1across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Upadacitinib

Brand: Rinvoq · 327K Part D claims (CY24) · 63K beneficiaries · First FDA approval: 2019-08-16

Brand-only (no generics) 1217 plans require PA

Low NADAC$228.83

→

Avg plan cost$306.03

Part D spend $2.41B 1× spread, current vs floor

Class share

97%

of class CY24 spend

View profile →

Baricitinib

Brand: Olumiant · 15K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2018-05-31

1 generic mfrs 98 plans require PA

Low NADAC$92.29

→

Avg plan cost$138.48

Part D spend $56.8M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Abrocitinib

Brand: CIBINQO · 5K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2022-02-24

Brand-only (no generics) 85 plans require PA

Low NADAC$197.20

→

Avg plan cost$197.20

Part D spend $29.9M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Delgocitinib

Brand: Anzupgo · — Part D claims (CY24) · First FDA approval: 2025-07-24

Brand-only (no generics) 12 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.